Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea
July 31, 2018 04:00 ET
|
Helsinn Healthcare S.A.
Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea CINV is one of the most common and distressing side effects of cancer chemotherapyIncluded as a treatment option...